Recursion Gains 4% on FDA Phase 3 Alignment for Rare Disease Drug REC-4881
Recursion shares rose 4% after the FDA aligned on a Phase 3 trial design for REC-4881 in FAP, clearing a path for late-stage development in 2027.

Recursion Pharmaceuticals gained roughly 4% on Wednesday after the company announced U.S. Food and Drug Administration alignment on the registrational Phase 3 trial design for its lead rare-disease candidate, REC-4881. The agreement marks a critical regulatory milestone for the tech-enabled biotech's clinical pipeline in a condition with zero approved pharmacological treatments, even as commercialization remains years away.
What happened
Recursion (NASDAQ: RXRX) announced Wednesday that it reached alignment with the FDA on key parameters for its upcoming Phase 3 trial in familial adenomatous polyposis (FAP). Shares closed Wednesday at $2.83, up roughly 4% from the prior session's close of $2.72, bringing the company's market capitalisation to roughly $1.8 billion based on approximately 623 million shares outstanding.
The planned randomized, double-blind, placebo-controlled study will evaluate a 4 mg dose of REC-4881—an oral MEK1/2 inhibitor repositioned for FAP via Recursion's AI-enabled phenotypic screening platform—in approximately 200 post-colectomy adult FAP patients. Crucially, the FDA accepted a composite event-free survival primary endpoint that includes the excision of adenomas measuring 10 millimeters or larger across the gastrointestinal tract, alongside FAP-related surgery, development of high-grade dysplasia or cancer, or death from any cause. Secondary endpoints will evaluate total polyp burden and progression on the modified Spigelman scale. Recursion stated that trial initiation remains slated for the second half of 2027.
Why it matters
FAP is an inherited genetic condition caused by mutations in the APC gene that leads to hundreds of precancerous polyps and a near-certain lifetime risk of colorectal cancer without intervention. Patients frequently undergo complete surgical removal of the colon or rectum, yet polyps routinely recur in the pouch or duodenum, leaving patients with no approved drugs and limited options beyond repeated endoscopic surgeries.
Securing an objective endpoint like 10-millimeter polyp excision within a composite event-free survival framework provides clear regulatory clarity for Phase 3 execution. However, the multi-year timeline tempers immediate enthusiasm: with enrollment starting in late 2027, commercialization remains distant. Recursion's balance sheet provides runway. Bolstered by an October follow-on offering that netted $187.2 million, pro forma cash stood at approximately $748.7 million at the end of the third quarter, extending its operational runway into 2029.
What to watch next
- TUPELO trial updates: Additional Phase 1b/2 clinical data and polyp reduction metrics across 2027.
- H2 2027 Phase 3 launch: Site initiation and first patient dosing across the U.S. and Europe.
- Operating cash burn: Execution against management's target of under $360 million in cash expenses for 2027 as prudent risk management against further dilution.
Sources (3)
This analysis is for information only and is not investment advice. Prices and figures as of publication.